Microba Life Sciences Limited (MAP.AX)
AUD 0.19
(0.0%)
AUD 0.19
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 395.38 Thousand AUD | 38.95% |
| 2023 | 1.13 Million AUD | -14.11% |
| 2022 | 1.32 Million AUD | 392.58% |
| 2021 | 269.01 Thousand AUD | -52.27% |
| 2020 | 563.64 Thousand AUD | 38.7% |
| 2019 | 406.37 Thousand AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 628.73 Thousand AUD | -52.55% |
| 2024 Q4 | 395.38 Thousand AUD | 0.0% |
| 2024 Q2 | 1.37 Million AUD | 119.28% |
| 2024 FY | 1.58 Million AUD | 38.95% |
| 2023 Q3 | 592.79 Thousand AUD | -50.07% |
| 2023 FY | 1.13 Million AUD | -14.11% |
| 2023 Q4 | 1.32 Million AUD | 123.54% |
| 2023 Q2 | 1.18 Million AUD | 100.29% |
| 2023 Q1 | 592.73 Thousand AUD | -55.27% |
| 2022 FY | 1.32 Million AUD | 392.58% |
| 2022 Q4 | 1.32 Million AUD | 56.3% |
| 2022 Q3 | 847.82 Thousand AUD | -21.05% |
| 2022 Q2 | 1.07 Million AUD | 51.76% |
| 2022 Q1 | 707.59 Thousand AUD | 163.03% |
| 2021 Q3 | 175.65 Thousand AUD | 0.0% |
| 2021 FY | 269.01 Thousand AUD | -52.27% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 Q4 | 269.01 Thousand AUD | 53.15% |
| 2020 FY | 563.64 Thousand AUD | 38.7% |
| 2019 FY | 406.37 Thousand AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Australian Clinical Labs Limited | 308.89 Million AUD | 99.872% |
| BCAL Diagnostics Limited | 641.34 Thousand AUD | 38.35% |
| Genetic Signatures Limited | 1.22 Million AUD | 67.618% |
| Genetic Technologies Limited | 643.54 Thousand AUD | 38.561% |
| Healius Limited | 1.59 Billion AUD | 99.975% |
| Imagion Biosystems Limited | 6.03 Million AUD | 93.452% |
| Integral Diagnostics Limited | 357.79 Million AUD | 99.889% |
| INOVIQ Ltd | 535.05 Thousand AUD | 26.104% |
| Monash IVF Group Limited | 59.56 Million AUD | 99.336% |
| Rhythm Biosciences Limited | 163.82 Thousand AUD | -141.352% |
| Sonic Healthcare Limited | 4.51 Billion AUD | 99.991% |